Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma

Hepato-Gastroenterology

Volumn 59, Issue 113, 2012, Pages 141-146

  Zhang, Weimin ^a   Li, Chen ^b   Wang, Jing ^b   He, Chao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

FAS; FASL; Gastric cardiac adenocarcinoma; Interaction; Smoking

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ARTICLE; CANCER RISK; DISEASE COURSE; DNA POLYMORPHISM; GASTRIC CARDIAC ADENOCARCINOMA; GENETIC PREDISPOSITION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD95; CARDIA; CASE-CONTROL STUDIES; CHINA; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; SMOKING; STOMACH NEOPLASMS;

EID: 84863235839     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11300     Document Type: Article

References (29)

1. Fan XQ, Guo YJ: Apoptosis in oncology. Cell Res 2001; 11(1):1-7.
2. Evan GI, Vousden KH: Cell cycle and apoptosis in cancer. Nature 2001; 17:342-348.
3. Andera L: Signaling activated by the death receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(3):173-180.
4. Kim R, Emi M, Tanabe K, Uchida Y, Toge T: The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100(11):2281-2291. (Pubitemid 38657874)
5. Reichmann E: The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002; 12(4):309-315.
6. Randhawa SR, Chahine BG, Lowery-Nordberg M, Cotelingam JD, Casillas AM: Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. Ann Allergy Asthma Immunol 2010; 104(4):286-292.
7. Houston A, O'Connell J: The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4(4):321-326. (Pubitemid 38987056)
8. Wajant H: The Fas signaling pathway: more than a paradigm. Science 2002; 296(5573):1635-1636.
9. Huang QR, Morris D, Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34(8-9):577-582. (Pubitemid 27512871)
10. Wu J, Metz C, Xu X: A novel polymorphic AAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression, a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 170:132-138. (Pubitemid 36026132)
11. Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z: The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009; 17(10):1294-1303.
12. Zhang Z, Xue H, Gong W: FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009; 30:487-493.
13. Moore MA, Eser S, Igisinov N: Cancer epidemiology and control in North-Western and Central Asia - past, present and future. Asian Pac J Cancer Prev 2010; 11:17-32.
14. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56:1-9. (Pubitemid 36183309)
15. Compare D, Rocco A, Nardone G: Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010; 14:302-308.
16. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y, Lin D: Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42(6):479-484. (Pubitemid 40847235)
17. Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23:381-387.
18. Baldini E, Ulisse S, Marchioni E, Di BA, Giovannetti G, Petrangeli E, Sentinelli S, Donnorso R, Reale M, Mottolese M, Gandini L, Lenzi A, D'Armiento M: Expression of Fas and Fas ligand in human testicular germ cell tumours. Int J Androl 2009; 32(2):123-130.
19. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG: Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005; 96(3):705-713. (Pubitemid 40255490)
20. Kang S, Dong SM, Seo SS, Kim JW, Park SY: FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 2008; 180(1):1-5. (Pubitemid 350199691)
21. Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, Lou YF, Tang YN, Jiang X, Lu GS, Zhang J: FASLG polymorphism is associated with cancer risk. Eur J Cancer 2009; 45:2574-2578.
22. Qiu LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, Li J, Zheng MH: FAS-1377 G/A polymorphism is associated with cancer susceptibility, evidence from 10,564 cases and 12,075 controls. Hum Genet 2009; 125:431-435.
23. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y: Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma. J Gastroenterol Hepatol 2010; 25(3):555-561.
24. Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, Zhang Z: FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 2009; 47(7-8):559-568.
25. Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y: Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000; 32:761-769.
26. Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, Liu J, Zhao D, Li H, Tan W, Lin D: Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008; 14(10):3230-3236.
27. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D: Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28(5):1067-1073. (Pubitemid 47072192)
28. Bijl M, Horst G, Limburg PC, Kallenberg CG: Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin invest 2001; 31:550-553. (Pubitemid 32579393)
29. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T: Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999; 192:48-53. (Pubitemid 29133838)